AR124194A1 - Proceso para la preparación de (9s)-n-[3-(6-metilpirimidin-4-il)-3-azabiciclo[3.2.1]octan-8-il]-9-(2,3,4-trifluorofenil)-6,7,8,9-tetrahidro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amina y su forma sólida - Google Patents
Proceso para la preparación de (9s)-n-[3-(6-metilpirimidin-4-il)-3-azabiciclo[3.2.1]octan-8-il]-9-(2,3,4-trifluorofenil)-6,7,8,9-tetrahidro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amina y su forma sólidaInfo
- Publication number
- AR124194A1 AR124194A1 ARP210103410A ARP210103410A AR124194A1 AR 124194 A1 AR124194 A1 AR 124194A1 AR P210103410 A ARP210103410 A AR P210103410A AR P210103410 A ARP210103410 A AR P210103410A AR 124194 A1 AR124194 A1 AR 124194A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- solid form
- preparation
- formation
- reaction
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 10
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 abstract 2
- 238000006880 cross-coupling reaction Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- MVAXKFAQKTWRAH-UHFFFAOYSA-N 4-chloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC=N1 MVAXKFAQKTWRAH-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 208000017004 dementia pugilistica Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere al proceso para la preparación de un compuesto (1), y su forma sólida, que es un modulador de g-secretasa y puede ser útil para la profilaxis y el tratamiento de una enfermedad asociada al depósito de b-amiloide en el cerebro, en particular la enfermedad de Alzheimer, y otras enfermedades, tales como angiopatía amiloide cerebral, hemorragia cerebral hereditaria con amiloidosis, tipo holandés (HCHWA-D), demencia multiinfarto, demencia pugilística y síndrome de Down. Reivindicación 1: Un proceso para la preparación de un compuesto (1), que comprende las siguientes etapas: etapa a) formación del compuesto (3), mediante la reacción del compuesto (2), y 4-cloro-6-metil-pirimidina; etapa b) formación del compuesto (4), mediante la reacción de desprotección del compuesto (3) y la formación de sal de HCl; etapa c) acoplamiento cruzado que forma el compuesto (1), mediante la reacción de acoplamiento cruzado de Buchwald del compuesto (4) y compuesto (5). Reivindicación 19: Una forma sólida del compuesto (1), en donde la forma sólida es la forma A que exhibe un patrón de difracción de rayos X de polvo (XRPD) con picos característicos expresados en grados 2-q a 10,0º ± 0,2º, 15,6º ± 0,2º, 16,1º ± 0,2º, 18,4º ± 0,2º, 19,3º ± 0,2º, 20,1º ± 0,2º y 21,8º ± 0,2º.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020135740 | 2020-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124194A1 true AR124194A1 (es) | 2023-02-22 |
Family
ID=79092930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103410A AR124194A1 (es) | 2020-12-11 | 2021-12-09 | Proceso para la preparación de (9s)-n-[3-(6-metilpirimidin-4-il)-3-azabiciclo[3.2.1]octan-8-il]-9-(2,3,4-trifluorofenil)-6,7,8,9-tetrahidro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amina y su forma sólida |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240018143A1 (es) |
| EP (1) | EP4259630A1 (es) |
| JP (1) | JP2023553051A (es) |
| KR (1) | KR20230118102A (es) |
| CN (1) | CN116685589A (es) |
| AR (1) | AR124194A1 (es) |
| AU (1) | AU2021393968A1 (es) |
| CA (1) | CA3199042A1 (es) |
| IL (1) | IL303507A (es) |
| MX (1) | MX2023006715A (es) |
| TW (1) | TW202235076A (es) |
| WO (1) | WO2022122864A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2784769A1 (en) | 2010-01-15 | 2011-07-21 | Janssen Pharmaceuticals, Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| JP6980751B2 (ja) * | 2016-07-14 | 2021-12-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 縮合ピリミジン誘導体 |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| CN109641912B (zh) | 2016-11-01 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| EP3743428B1 (en) | 2018-01-22 | 2022-01-19 | F. Hoffmann-La Roche AG | Triazolo-azepine derivatives |
| ES2940185T3 (es) | 2018-12-27 | 2023-05-04 | Hoffmann La Roche | Procedimiento para la preparación de exo-N-(3-azabiciclo[3.2.1]octan-8-il)carbamato de terc-butilo |
| WO2021105337A1 (en) * | 2019-11-29 | 2021-06-03 | F. Hoffmann-La Roche Ag | Process for the preparation (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine |
-
2021
- 2021-12-09 AU AU2021393968A patent/AU2021393968A1/en active Pending
- 2021-12-09 WO PCT/EP2021/084887 patent/WO2022122864A1/en active Application Filing
- 2021-12-09 AR ARP210103410A patent/AR124194A1/es unknown
- 2021-12-09 IL IL303507A patent/IL303507A/en unknown
- 2021-12-09 KR KR1020237019521A patent/KR20230118102A/ko unknown
- 2021-12-09 JP JP2023534366A patent/JP2023553051A/ja active Pending
- 2021-12-09 EP EP21831292.4A patent/EP4259630A1/en active Pending
- 2021-12-09 CA CA3199042A patent/CA3199042A1/en active Pending
- 2021-12-09 MX MX2023006715A patent/MX2023006715A/es unknown
- 2021-12-09 CN CN202180078465.7A patent/CN116685589A/zh active Pending
- 2021-12-10 TW TW110146264A patent/TW202235076A/zh unknown
-
2023
- 2023-06-08 US US18/331,792 patent/US20240018143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116685589A (zh) | 2023-09-01 |
| MX2023006715A (es) | 2023-06-23 |
| AU2021393968A1 (en) | 2023-05-11 |
| JP2023553051A (ja) | 2023-12-20 |
| TW202235076A (zh) | 2022-09-16 |
| CA3199042A1 (en) | 2022-06-16 |
| WO2022122864A1 (en) | 2022-06-16 |
| KR20230118102A (ko) | 2023-08-10 |
| US20240018143A1 (en) | 2024-01-18 |
| EP4259630A1 (en) | 2023-10-18 |
| IL303507A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161742T1 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| JP2017536102A5 (es) | ||
| DOP2013000194A (es) | Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos | |
| JP2018519810A5 (es) | ||
| HRP20160415T1 (hr) | Inhibitori beta-sekretaze | |
| CA2822059A1 (en) | Inhibitors of influenza viruses replication | |
| MX2013006836A (es) | Inhibidores de la replicacion de los virus de la influenza. | |
| JP2013534256A5 (es) | ||
| JP2016503010A5 (es) | ||
| ECSP088338A (es) | Terapia de combinación de oxazolidinonas sustituidas para la profilaxis y el tratamiento de alteraciones del flujo sanguíneo cerebral | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| AR081154A1 (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y metodos de uso | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| MX344696B (es) | Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson. | |
| BR112019008295A2 (pt) | composto inibidor de multiquinase, e forma cristalina e utilização do mesmo | |
| AR124194A1 (es) | Proceso para la preparación de (9s)-n-[3-(6-metilpirimidin-4-il)-3-azabiciclo[3.2.1]octan-8-il]-9-(2,3,4-trifluorofenil)-6,7,8,9-tetrahidro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amina y su forma sólida | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| AR081389A1 (es) | Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma. | |
| ES2871574T3 (es) | Combinación de anticuerpo anti CD19 con un inhibidor de BCL-2 y usos de la misma | |
| US11702403B2 (en) | EAAT2 activators and methods of using thereof | |
| WO2018027037A3 (en) | Reelin compositions for treatment of neurological disorders | |
| JP2014500885A5 (es) | ||
| JP6491213B2 (ja) | 疼痛および他の障害の治療のためのガンマ−アミノ酪酸（ｇａｂａ）類似体 | |
| SI3033327T1 (en) | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE | |
| CO6660425A2 (es) | Compuestos para el tratamiento de trastornos neurológicos |